肿瘤细胞治疗研究
英文原题：CAR-T therapy dilemma and innovative design strategies for next generation.
嵌合抗原受体（CAR）T 细胞疗法对血液肿瘤显示出显著疗效，推动了 CAR-T 相关研究的指数级增长。
嵌合抗原受体（CAR）T 细胞疗法对血液系统肿瘤显示出显著治愈作用，推动 CAR-T 相关研究呈指数级增长。尽管靶向 CD19 的 CAR-T 疗法在临床试验中显示巨大希望，仍不断出现障碍，限制其在肿瘤免疫治疗中的疗效。CAR-T 肿瘤治疗面临的“困境”包括致死性细胞毒性、迁移受限、肿瘤浸润不足、免疫抑制微环境、免疫耐药和效力有限。解决 CAR-T 疗法困境需要跨学科策略，包括基于合成生物学的开关系统、生物指令性支架、纳米材料、溶瘤病毒、CRISPR 筛选、肠道微生物群及其代谢物。本综述介绍并总结这些跨学科创新技术，用于设计和递送下一代 CAR-T 细胞，以克服当前 CAR-T 的关键障碍。
Chimeric antigen receptor (CAR)-T-cell therapy has shown remarkable curative effects on hematological tumors, driving the exponential growth in CAR-T-related research. Although CD19-targeting CAR-T-cell therapy has displayed remarkable promise in clinical trials, many obstacles are arising that limit its therapeutic efficacy in tumor immunotherapy. The "dilemma" of CAR-T cell-based tumor therapy includes lethal cytotoxicity, restricted trafficking, limited tumor infiltration, an immunosuppressive microenvironment, immune resistance and limited potency. The solution to CAR-T-cell therapy's dilemma requires interdisciplinary strategies, including synthetic biology-based ON/OFF switch, bioinstructive scaffolds, nanomaterials, oncolytic viruses, CRISPR screening, intestinal microbiota and its metabolites. In this review, we will introduce and summarize these interdisciplinary-based innovative technologies for the next generation CAR-T-cell design and delivery to overcome the key barriers of current CAR-T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
